112 related articles for article (PubMed ID: 16301357)
21. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
[TBL] [Abstract][Full Text] [Related]
22. [Ventricular arrhythmias. A potential risk associated with the use of non-cardiovascular drugs prolonging the QT interval].
Calderone V; Cavero I
Minerva Med; 2002 Jun; 93(3):181-97. PubMed ID: 12094149
[TBL] [Abstract][Full Text] [Related]
23. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
Di Diego JM; Belardinelli L; Antzelevitch C
Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
[TBL] [Abstract][Full Text] [Related]
24. Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current.
Yang T; Chun YW; Stroud DM; Mosley JD; Knollmann BC; Hong C; Roden DM
Circulation; 2014 Jul; 130(3):224-34. PubMed ID: 24895457
[TBL] [Abstract][Full Text] [Related]
25. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations.
Remme CA; Wilde AA; Bezzina CR
Trends Cardiovasc Med; 2008 Apr; 18(3):78-87. PubMed ID: 18436145
[TBL] [Abstract][Full Text] [Related]
26. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
27. Differential modulation of late sodium current by protein kinase A in R1623Q mutant of LQT3.
Tsurugi T; Nagatomo T; Abe H; Oginosawa Y; Takemasa H; Kohno R; Makita N; Makielski JC; Otsuji Y
Life Sci; 2009 Mar; 84(11-12):380-7. PubMed ID: 19167409
[TBL] [Abstract][Full Text] [Related]
28. A molecular basis for the therapy of the long QT syndrome.
Priori SG; Napolitano C; Schwartz PJ
Arch Mal Coeur Vaiss; 1996 Sep; 89(9):1185-7. PubMed ID: 8952843
[TBL] [Abstract][Full Text] [Related]
29. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
30. Rate-dependent QT shortening mechanism for the LQT3 deltaKPQ mutant.
Nagatomo T; January CT; Ye B; Abe H; Nakashima Y; Makielski JC
Cardiovasc Res; 2002 Jun; 54(3):624-9. PubMed ID: 12031708
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel.
Kambouris NG; Nuss HB; Johns DC; Tomaselli GF; Marban E; Balser JR
Circulation; 1998 Feb; 97(7):640-4. PubMed ID: 9495298
[TBL] [Abstract][Full Text] [Related]
32. Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome.
Nuyens D; Stengl M; Dugarmaa S; Rossenbacker T; Compernolle V; Rudy Y; Smits JF; Flameng W; Clancy CE; Moons L; Vos MA; Dewerchin M; Benndorf K; Collen D; Carmeliet E; Carmeliet P
Nat Med; 2001 Sep; 7(9):1021-7. PubMed ID: 11533705
[TBL] [Abstract][Full Text] [Related]
33. Tubulin polymerization modifies cardiac sodium channel expression and gating.
Casini S; Tan HL; Demirayak I; Remme CA; Amin AS; Scicluna BP; Chatyan H; Ruijter JM; Bezzina CR; van Ginneken AC; Veldkamp MW
Cardiovasc Res; 2010 Mar; 85(4):691-700. PubMed ID: 19861310
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanism for an inherited cardiac arrhythmia.
Bennett PB; Yazawa K; Makita N; George AL
Nature; 1995 Aug; 376(6542):683-5. PubMed ID: 7651517
[TBL] [Abstract][Full Text] [Related]
35. Gene mutations associated with atrioventricular block complicated by long QT syndrome.
Nishizaki M; Hiraoka M
Circ J; 2010 Nov; 74(12):2546-7. PubMed ID: 21088333
[No Abstract] [Full Text] [Related]
36. A de novo missense mutation of human cardiac Na+ channel exhibiting novel molecular mechanisms of long QT syndrome.
Makita N; Shirai N; Nagashima M; Matsuoka R; Yamada Y; Tohse N; Kitabatake A
FEBS Lett; 1998 Feb; 423(1):5-9. PubMed ID: 9506831
[TBL] [Abstract][Full Text] [Related]
37. A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents.
Shuraih M; Ai T; Vatta M; Sohma Y; Merkle EM; Taylor E; Li Z; Xi Y; Razavi M; Towbin JA; Cheng J
J Cardiovasc Electrophysiol; 2007 Apr; 18(4):434-40. PubMed ID: 17331104
[TBL] [Abstract][Full Text] [Related]
38. Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.
Priori SG; Napolitano C
Cardiovasc Drugs Ther; 2002 Mar; 16(2):89-92. PubMed ID: 12090900
[TBL] [Abstract][Full Text] [Related]
39. Cisapride and torsades de pointes in a pacemaker patient.
Ng KS; Tham LS; Tan HH; Chia BL
Pacing Clin Electrophysiol; 2000 Jan; 23(1):130-2. PubMed ID: 10666763
[No Abstract] [Full Text] [Related]
40. Promoting arrhythmia susceptibility.
Bunch TJ; Ackerman MJ
Circulation; 2006 Jan; 113(3):330-2. PubMed ID: 16432063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
